No Data
No Data
Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Market Cap Rose CN¥397m Last Week; Retail Investors Who Hold 56% Profited and so Did Insiders
shanghai kaibao pharmaceutical (300039.SZ): The company's products Phlegm-heat-clearing injection and Phlegm-heat-clearing capsules are currently not being sold in the Hong Kong and Taiwan regions.
GeLonghui September 23rd | shanghai kaibao pharmaceutical (300039.SZ) stated on the investor interaction platform that the company's products Tan Reqing Injection and Tan Reqing Capsules are currently not sold in Hong Kong and Taiwan.
Shanghai Kaibao Pharmaceutical (300039.SZ): Currently, the company does not have any related products for the treatment of monkeypox.
Shanghai Kaibao (300039.SZ) stated on the investor interaction platform on September 23 that the company currently does not have any products for the treatment of monkeypox. The company's main product, Tanreqing Injection, is included in the clinical guidelines or treatment plans for prevention and control of "bird flu", "H1N1 flu", "H7N9 flu", "hand, foot and mouth disease", "dengue fever", "Ebola", "Middle East respiratory syndrome", and "COVID-19" by the National Health Commission and the Traditional Chinese Medicine Administration. In July 2024, the General Office of the National Health Commission issued the "Diagnosis and Treatment Plan for Measles and Other Infectious Diseases (2024 Edition)".
Shanghai Kaibao: Summary of the 2024 Semi-Annual Report
Shanghai Kaibao: 2024 Semi-Annual Report
Shanghai Kaibao (300039.SZ) released its performance for the first half of the year, with a net income of 0.142 billion yuan, a 5.07% increase.
Shanghai Kaibao (300039.SZ) released its 2024 semi-annual report. During the reporting period, the company achieved revenue...
No Data
No Data